MX2023014282A - Conjugados de neodegradador-anticuerpo anti-cumulo de diferenciación 33 (cd33). - Google Patents
Conjugados de neodegradador-anticuerpo anti-cumulo de diferenciación 33 (cd33).Info
- Publication number
- MX2023014282A MX2023014282A MX2023014282A MX2023014282A MX2023014282A MX 2023014282 A MX2023014282 A MX 2023014282A MX 2023014282 A MX2023014282 A MX 2023014282A MX 2023014282 A MX2023014282 A MX 2023014282A MX 2023014282 A MX2023014282 A MX 2023014282A
- Authority
- MX
- Mexico
- Prior art keywords
- neodadegrader
- cumule
- antibody conjugates
- differentiation
- differentiation antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163202272P | 2021-06-03 | 2021-06-03 | |
| US202163282588P | 2021-11-23 | 2021-11-23 | |
| PCT/IB2022/055168 WO2022254377A1 (en) | 2021-06-03 | 2022-06-02 | Neodegrader-anti-cd33 antibody conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014282A true MX2023014282A (es) | 2024-02-27 |
Family
ID=84323935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014282A MX2023014282A (es) | 2021-06-03 | 2022-06-02 | Conjugados de neodegradador-anticuerpo anti-cumulo de diferenciación 33 (cd33). |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240252671A1 (https=) |
| EP (1) | EP4346910A4 (https=) |
| JP (1) | JP2024521919A (https=) |
| KR (1) | KR20240042598A (https=) |
| AU (1) | AU2022284372A1 (https=) |
| CA (1) | CA3222185A1 (https=) |
| CL (2) | CL2023003605A1 (https=) |
| CO (1) | CO2023016712A2 (https=) |
| IL (1) | IL308812A (https=) |
| MX (1) | MX2023014282A (https=) |
| PE (1) | PE20250159A1 (https=) |
| TW (1) | TW202313022A (https=) |
| WO (1) | WO2022254377A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119212733A (zh) * | 2022-05-18 | 2024-12-27 | 苏州宜联生物医药有限公司 | 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途 |
| EP4667463A1 (en) * | 2023-02-15 | 2025-12-24 | CSPC Megalith Biopharmaceutical Co., Ltd. | Domide molecular glue derivative and use thereof |
| WO2024222841A1 (zh) * | 2023-04-27 | 2024-10-31 | 石药集团巨石生物制药有限公司 | 一种抗体药物偶联物 |
| WO2024249235A1 (en) * | 2023-06-01 | 2024-12-05 | Abbvie Inc. | Anti-human cd33 bet degrader antibody-drug conjugates |
| WO2025085489A1 (en) * | 2023-10-17 | 2025-04-24 | Bristol-Myers Squibb Company | Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2358697E (pt) * | 2008-10-29 | 2016-02-03 | Celgene Corp | Compostos de isoindolina para utilização no tratamento do cancro |
| PT2822575T (pt) * | 2012-03-03 | 2020-07-02 | Immungene Inc | Moléculas de fusão anticorpos-mutante de interferão modificadas |
| JP2018516950A (ja) * | 2015-06-12 | 2018-06-28 | イミュンジーン, インコーポレイテッドImmunGene, Inc. | がん治療のための集中インターフェロン免疫療法 |
| CN104994263B (zh) * | 2015-06-30 | 2016-12-28 | 广东欧珀移动通信有限公司 | 一种摄像装置及具有该摄像装置的终端 |
| BR112022019532A2 (pt) * | 2020-03-31 | 2022-12-06 | Orum Therapeutics Inc | Conjugados de neodegrader |
-
2022
- 2022-06-02 AU AU2022284372A patent/AU2022284372A1/en active Pending
- 2022-06-02 PE PE2023003198A patent/PE20250159A1/es unknown
- 2022-06-02 EP EP22815474.6A patent/EP4346910A4/en active Pending
- 2022-06-02 JP JP2023574587A patent/JP2024521919A/ja active Pending
- 2022-06-02 MX MX2023014282A patent/MX2023014282A/es unknown
- 2022-06-02 WO PCT/IB2022/055168 patent/WO2022254377A1/en not_active Ceased
- 2022-06-02 KR KR1020247000100A patent/KR20240042598A/ko active Pending
- 2022-06-02 US US18/566,805 patent/US20240252671A1/en active Pending
- 2022-06-02 CA CA3222185A patent/CA3222185A1/en active Pending
- 2022-06-02 IL IL308812A patent/IL308812A/en unknown
- 2022-06-02 TW TW111120735A patent/TW202313022A/zh unknown
-
2023
- 2023-12-01 CL CL2023003605A patent/CL2023003605A1/es unknown
- 2023-12-01 CO CONC2023/0016712A patent/CO2023016712A2/es unknown
-
2026
- 2026-02-10 CL CL2026000399A patent/CL2026000399A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024521919A (ja) | 2024-06-04 |
| AU2022284372A9 (en) | 2024-01-11 |
| CL2026000399A1 (es) | 2026-03-20 |
| TW202313022A (zh) | 2023-04-01 |
| CO2023016712A2 (es) | 2024-02-26 |
| IL308812A (en) | 2024-01-01 |
| AU2022284372A1 (en) | 2023-12-14 |
| EP4346910A4 (en) | 2026-05-06 |
| US20240252671A1 (en) | 2024-08-01 |
| PE20250159A1 (es) | 2025-01-22 |
| EP4346910A1 (en) | 2024-04-10 |
| WO2022254377A1 (en) | 2022-12-08 |
| CA3222185A1 (en) | 2022-12-08 |
| CL2023003605A1 (es) | 2024-05-03 |
| KR20240042598A (ko) | 2024-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023014282A (es) | Conjugados de neodegradador-anticuerpo anti-cumulo de diferenciación 33 (cd33). | |
| MX2022011825A (es) | Conjugados neodegradadores. | |
| CL2020001333A1 (es) | Moléculas de unión b7-h3 novedosas, conjugados anticuerpo-fármaco de los mismos y métodos de uso de los mismos. (divisional solicitud 201802895) | |
| MA39909B1 (fr) | Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer | |
| CL2023003604A1 (es) | Conjugados de neodegradadores | |
| CY1116913T1 (el) | Τροποποιημενα κλασματα fab αντισωματων | |
| EP1507556A4 (en) | Calicheamicin DERIVATIVE-carrier conjugates | |
| CY1125181T1 (el) | Ανοσοσυζευγματα που στοχευουν adam9 και μεθοδοι χρησης αυτων | |
| BR112019005697A2 (pt) | anticorpos anti-muc16-cd3 biespecíficos e conjugados de fármaco e anti-muc16 | |
| BR0112104A (pt) | Processos para tratamento de doenças reumáticas usando uma molécula de ctla4 solúvel | |
| BR112017019300A2 (pt) | conjugado de fórmula genérica ama - l - x - s - ab, método para sintetizar um conjugado de fórmula genérica ama - l - x - s - ab, kit, método para sintetizar o composto ama - l - x', composição farmacêutica e método para tratar uma doença associada a células que apresentam um alvo | |
| ATE476992T1 (de) | Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper | |
| EA202091161A1 (ru) | Конъюгаты антител против cd22 с майтанзином, их комбинации и способы применения | |
| AR069747A1 (es) | Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion | |
| BR112022024361A2 (pt) | Tubulisinas e conjugados de proteína-tubulisina | |
| DE602006016344D1 (de) | Für das fibroblastenaktivierungsprotein spezifische antikörpermoleküle und immunkonjugate, die diese enthalten | |
| MX2010005966A (es) | Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7). | |
| PE20170517A1 (es) | Conjugados de anticuerpo-farmaco-anti-ptk7 | |
| PE20140833A1 (es) | Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo | |
| AR034456A1 (es) | Champues con alcohol de behenilo | |
| PE20120902A1 (es) | Anticuerpos anti-egfl7 humanizados | |
| ATE304866T1 (de) | Chelatorkonjugate mit verbesserten eigenschaften | |
| CR20210324A (es) | Anticuerpos anti-pmel 17 y conjugados de los mismos | |
| WO2023141500A8 (en) | Nanobody-drug adducts and uses thereof | |
| EP4294441A4 (en) | ANTI-CLDN18.2 ANTIBODY CONJUGATES |